Schering-Plough, Chr. Hansen Holding A/S deal

SGP said it will not take an option to license Prograss, an oral tablet to treat grass pollen allergy from CHRH's ALK-Abello subsidiary. Under a 2002 deal, the companies partnered for Phase IIb/III de...